Annovis Bio

General Information


Annovis is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease in Down syndrome (AD-DS), Alzheimer’s disease (AD) and Parkinson’s disease (PD). We have an ongoing Phase 2a proof-of-concept study in AD patients and have planned to commence a second Phase 2a study in PD patients. We are developing our lead compound, ANVS-401, for chronic neurodegenerative diseases, such as AD-DS, AD and PD. In a number of studies, ANVS-401 inhibited the synthesis of neurotoxic proteins—APP/Ab (APP), tau/phospho-tau (tau) and a-Synuclein (a-SYN)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells.

Employees: 2
Founded: 2008
Contact Information
Address 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312, US
Phone Number (610) 727-3913
Web Address
View Prospectus: Annovis Bio
Financial Information
Market Cap $41.5mil
Revenues $0 mil (last 12 months)
Net Income $-0.95 mil (last 12 months)
IPO Profile
Symbol ANVS
Exchange NYSE - American
Shares (millions): 2.0
Price range $6.00 - $6.00
Est. $ Volume $12.0 mil
Manager / Joint Managers ThinkEquity (a division of Fordham Financial Management, Inc. )
CO-Managers -
Expected To Trade: 1/29/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change